1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. United States In-Vitro Diagnostics (IVD) Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing Prevalence of Chronic Diseases
3.2.1.2. Innovations in IVD Technology, such as Point-Of-Care Testing, Molecular Diagnostics, and Automation
3.2.1.3. Rising Healthcare Expenditure
3.2.1.4. Growing Awareness about Early Disease Detection
3.2.2. Restraints
3.2.2.1. Unfavorable Reimbursement Scenario
3.2.2.2. High Cost of Development
3.2.2.3. Stringent Regulatory Environment
3.2.3. Opportunities
3.2.3.1. Emerging Technologies such as Liquid Biopsy, Digital Pathology, and Microfluidics
3.2.3.2. Increasing Adoption of Personalized Medicine
3.2.3.3. Growing Demand for Rapid and Accessible Diagnostic Solutions
3.2.4. Challenges
3.2.4.1. Shortage of Skilled Professionals in the IVD Industry
3.2.4.2. Increasing Concerns about Data Privacy and Security
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. United States In-Vitro Diagnostics (IVD) Market: Marketing Strategies
5. United States In-Vitro Diagnostics (IVD) Market: Pricing Analysis
6. United States In-Vitro Diagnostics (IVD) Market Overview
6.1. Market Size & Forecast, 2019-2030
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Product and Services
6.2.1.1. Reagents & Kits
6.2.1.2. Instruments
6.2.1.3. Software & Services
6.2.2. By Technique
6.2.2.1. Molecular Diagnostics
6.2.2.2. Tissue Diagnostics
6.2.2.3. Clinical Chemistry
6.2.2.4. Immunodiagnostics
6.2.2.5. Hematology
6.2.2.6. Others
6.2.3. By Application
6.2.3.1. Infectious Diseases
6.2.3.2. Cancer
6.2.3.3. Cardiac Diseases
6.2.3.4. Immune System Disorders
6.2.3.5. Nephrological Diseases
6.2.3.6. Gastrointestinal Diseases
6.2.3.7. Others
6.2.4. By End User
6.2.4.1. Standalone Laboratories
6.2.4.2. Hospitals
6.2.4.3. Academic and Medical Schools
6.2.4.4. Point of Care
6.2.4.5. Others
7. Competitive Landscape
7.1. List of Key Players and Their Products
7.2. United States In-Vitro Diagnostics (IVD) Company Market Share Analysis, 2023
7.3. Competitive Benchmarking, By Operating Parameters
7.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
8. Impact of Escalating Geopolitical Tensions on United States In-Vitro Diagnostics (IVD) Market
9. Company Profiles (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook, and SWOT Analysis)
9.1. Roche Diagnostics
9.2. Abbott Laboratories
9.3. Siemens Healthineers
9.4. Danaher Corporation
9.5. Thermo Fisher Scientific
9.6. Johnson & Johnson
9.7. Ortho-Clinical Diagnostics
9.8. Sysmex Corporation
9.9. Bio-Rad Laboratories
9.10. bioMerieux
9.11. QIAGEN
9.12. Becton, Dickinson and Company
9.13. Other prominent players
10. Key Strategic Recommendations
11. Research Methodology
11.1. Qualitative Research
11.1.1. Primary & Secondary Research
11.2. Quantitative Research
11.3. Market Breakdown & Data Triangulation
11.3.1. Secondary Research
11.3.2. Primary Research
11.4. Breakdown of Primary Research Respondents
11.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.